Puma Biotechnology

421 articles about Puma Biotechnology

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 06, 2023

  6/6/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 2, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

  6/4/2023

  Puma Biotechnology, Inc. announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone in metastatic hormone receptor positive and triple negative breast cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2-6 in Chicago and online.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Reports First Quarter Financial Results

  5/4/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023.

• Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

  4/20/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 11, 2023

  4/11/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on April 8, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,000 shares of Puma common stock to four new non-executive employees.

• Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

  3/14/2023

  Puma Biotechnology, Inc. announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast cancer.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023

  3/3/2023

  Puma Biotechnology, Inc. announced that on March 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 9,375 shares of Puma common stock to one new non-executive employee.

• Puma Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results

  3/2/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2022.

• Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference

  2/28/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend Cowen’s 43rd Annual Health Care Conference, which will be held March 6 – 8, 2023 at the Boston Marriott Copley Place in Boston.

• Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

  2/16/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 2, 2023, following the release of its fourth quarter and full year 2022 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 07, 2023

  2/7/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on February 6, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 34,163 shares of Puma common stock to four new non-executive employees.

• Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

  2/1/2023

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Breast Cancer were updated to include an addition involving neratinib (NERLYNX ® ).

• Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference

  1/12/2023

  Puma Biotechnology, Inc. will provide an overview of the Company at 11:00 a.m. PST/2:00 p.m. EST on January 19 at the virtual B. Riley Securities’ 3rd Annual Oncology Conference.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jan 11, 2023

  1/11/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on January 10, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,250 shares of Puma common stock to four new non-executive employees.

• Puma Biotechnology Releases Updated Corporate Presentation - Jan 09, 2023

  1/9/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, will refer to in meetings beginning Monday, January 9, 2023.

• Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium

  12/7/2022

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2022

  12/5/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Reports Third Quarter 2022 Financial Results

  11/3/2022

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2022.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2022

  11/2/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on November 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,250 shares of Puma common stock to two new non-executive employees.